Riskpilot← Back to searchSign inGet full accessCamurus ApS
APSActiveCVR 40486585Axeltorv 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20194 employees
Revenue 2024
DKK 2,8M
+2% vs 2023
EBITDA margin
10.9%
-20% vs 2023
Equity ratio
57.1%
Financial strength
Net profit 2024
DKK 190K
-23% vs 2023
| Revenue | DKK 2,8M | +2% |
| EBITDA | DKK 300K | -20% |
| Net profit | DKK 190K | -23% |
| Total assets | DKK 1,7M | +1% |
| Equity | DKK 978K | +24% |
| Employees | 4 | — |
Legal name
Camurus ApS
CVR number
40486585
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
22. april 2019
Share capital
DKK 180.000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to medlemmer af direktionen i forening.
Company purpose
Selskabets formål er at drive virksomhed inden for salg og marketing, herunder med medicinalprodukter, og hvad der efter direktionens skøn måtte være beslægtet hermed.
Address
Axeltorv 2
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 690 | 1.205 | 1.019 | 1.373 | 2.705 | 2.768 |
| Staff expenses | -661 | -975 | -841 | -1.160 | -2.331 | -2.468 |
| EBITDA | 30 | 231 | 179 | 213 | 373 | 300 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 30 | 231 | 179 | 213 | 373 | 300 |
| Net financials | -2 | -3 | -8 | -6 | -11 | 38 |
| Profit before tax | 28 | 228 | 171 | 207 | 362 | 338 |
| Tax | 19 | 79 | 75 | 98 | 115 | 149 |
| Net profit | 9 | 149 | 95 | 109 | 247 | 190 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 384 | 743 | 692 | 968 | 1.690 | 1.714 |
| Equity | 189 | 338 | 433 | 542 | 789 | 978 |
| Long-term debt | 35 | 100 | 0 | 0 | 0 | 0 |
| Short-term debt | 160 | 305 | 255 | 426 | 902 | 736 |
| Total debt | 195 | 405 | 255 | 426 | 902 | 736 |
EBITDA margin
10.9%
This company
15.8%
Market median
-31% vs market
20192024
Equity ratio
57.1%
This company
38.2%
Market median
+49% vs market
20192024
Return on equity
19.4%
This company
18.4%
Market median
+5% vs market
20192024
Net profit margin
6.8%
This company
8.1%
Market median
-16% vs market
20192024
Asset turnover
1.62×
This company
1.12×
Market median
+45% vs market
20192024
Debt / equity
0.75×
This company
0.62×
Market median
+21% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-04-22 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SF Management | Management | 2019 | — | — |
EM Management | Management | 2019 | — | — |
JU Management | Management | 2022 | — | — |
AV Management | Management | 2025 | — | — |
RM Management | Management | 2019 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Camurus ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sven Fredrik Tiberg | Management | 0 companies |
| Eva Maria Pinotti Lindqvist | Management | 0 companies |
| Jon Uguzne Garay Olonso | Management | 0 companies |
| Anders Vadsholt | Management | 0 companies |
| Richard Major Jameson | Management | 0 companies |